4.8 Article

Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2

期刊

NATURE COMMUNICATIONS
卷 5, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms4477

关键词

-

资金

  1. Fondation 'Sante , Sport et Developpement Durable-Universite Aix-Marseille'
  2. ARC French Foundation for Cancer Research
  3. French Agence National de Recherche sur le SIDA et les hepatites virales (ANRS)
  4. ARC French Foundation for Cancer Research [PDF20121206161, SFI20121205596]
  5. Fund for Scientific Research - Flanders (FWO) [G.0479.12]
  6. Institut National du Cancer [2013-105]
  7. Belgian Foundation against cancer (BFK) [214-2008]
  8. Concerted Actions Program of KU Leuven [GOA/12/016]

向作者/读者索取更多资源

Exosomes are small vesicles that are secreted by cells and act as mediators of cell to cell communication. Because of their potential therapeutic significance, important efforts are being made towards characterizing exosomal contents. However, little is known about the mechanisms that govern exosome biogenesis. We have recently shown that the exosomal protein syntenin supports exosome production. Here we identify the small GTPase ADP ribosylation factor 6 (ARF6) and its effector phospholipase D2 (PLD2) as regulators of syntenin exosomes. ARF6 and PLD2 affect exosomes by controlling the budding of intraluminal vesicles (ILVs) into multivesicular bodies (MVBs). ARF6 also controls epidermal growth factor receptor degradation, suggesting a role in degradative MVBs. Yet ARF6 does not affect HIV-1 budding, excluding general effects on Endosomal Sorting Complexes Required for Transport. Our study highlights a novel pathway controlling ILV budding and exosome biogenesis and identifies an unexpected role for ARF6 in late endosomal trafficking.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据